Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic dataL.A. Marques Da Costa, Juan C. Cervellino, Carlos Martín Molina et al.|Anti-Cancer Drugs|1997Cited by 26
Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companiesJuan C. Cervellino, Roberto A. Díez, Sandra B. Corazza et al.|Revista Panamericana de Salud Pública|2003Cited by 7